{
    "2018-09-10": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Apple, Snap Weak Again; Will This Sector Help Dow Beat Nasdaq In Q3?",
                "features": {
                    "keywords": [
                        "Apple",
                        "Snap",
                        "Weak",
                        "Dow",
                        "Nasdaq",
                        "Q3"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Monday's ETF with Unusual Volume: XRLV",
                "features": {
                    "keywords": [
                        "ETF",
                        "Unusual Volume",
                        "XRLV"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "financial instruments"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Analysts",
                        "Top Dow 30 Picks"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis a Top Ranked SAFE Dividend Stock With 3.6% Yield",
                "features": {
                    "keywords": [
                        "Novartis",
                        "SAFE Dividend",
                        "Stock",
                        "Yield"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Novartis",
                        "AstraZeneca",
                        "Merck",
                        "Pfizer",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Exelixis' Cabometyx Recommended by NCCN for All Types of RCC",
                "features": {
                    "keywords": [
                        "Exelixis",
                        "Cabometyx",
                        "NCCN",
                        "RCC"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}